Fate Therapeutics (FATE) Cindy Tahl Sells Shares

What Happened
Cindy Tahl, Chief Legal & Compliance Officer of Fate Therapeutics (FATE), sold 38,800 shares on August 4, 2026 in an open-market/private sale to cover tax withholding related to vesting restricted stock units (RSUs). The weighted-average sale price was $2.46 per share for gross proceeds of approximately $95,405. The sale was automatic under an irrevocable sell-to-cover election and was not a discretionary trade.

Key Details

• Transaction date: 2026-08-04; Form 4 filed 2026-08-05 (timely filing).
• Shares sold: 38,800; weighted-average sale price: $2.46; price range reported: $2.415–$2.540.
• Total proceeds: ~$95,405.
• Reason: Sale to satisfy tax withholding for the vesting of 75,000 RSUs granted July 29, 2024 (footnote). These sales were automatically executed per an irrevocable sell-to-cover election (not discretionary).
• Additional disclosure: Reporting person will provide, on request, the number of shares sold at each price within the reported range.
• Shares owned after the transaction: not specified in the provided filing excerpt.

Context
This was a routine sell-to-cover tax withholding transaction tied to RSU vesting, not an opportunistic open-market sale by choice. Such transactions are common when equity awards vest and do not necessarily indicate insider sentiment about the company’s prospects.